EDX Medical Group plc (LON:EDX) is a UK-based listed company focused on the development of diagnostic tests that enable personalised treatment for cancer, cardiovascular and infectious diseases.
EDX Medical specialises in Oncology, Cardiology, and Infectious Diseases.
Prostate cancer ‘super test’
The EDX test identifies the presence or absence of cancerous cells, signs of early and late-stage cancer, whether it is slow or aggressive as well as genetic and hereditary risks in the patient.
The EDX test involves studying the most comprehensive combination of clinically-validated prostate-related biomarkers currently known, in both blood and urine samples. The interpretation of these biomarkers using a proprietary AI-driven algorithm highlights early signs of cancer and characteristic features that can guide treatment selection.
BC95 – Advanced Bowel Cancer Testing Service
The BC95 service increases the accuracy of testing and includes an assessment of the patient’s hereditary risk of bowel cancer. It is the most advanced and accurate testing solution to be offered in the UK with sensitivities in excess of 95% across stages 1 to 4 of bowel cancer.
The EDX Medical BC95 bowel cancer service provides an analysis of a comprehensive panel of hereditary genetic risks, plus the most reliable early detection test and a reference test for faecal haemoglobin, enabling comparison to current NHS practice.
TC100 – Combined Blood Testing for Testicular Germ Cell Tumours
The TC100 service is based on a simple blood sample which is taken by a health professional and sent for laboratory analysis.
The service encompasses a range of biomarkers that enable the detection of very early signs of the disease in a small blood sample, allowing healthcare professionals to confirm the presence or absence of testicular cancer in men from a range of ethnicities and ages with ultra-high accuracy. Testicular cancer can be treated very successfully if detected early.
Hereditary Cancer Testing – Multi-Gene Germline Panel
EDX Medical’s comprehensive hereditary germline cancer testing products will enable doctors to advise family members of cancer patients on lifestyle choices and actions they can take to delay or prevent onset of the disease. Family members include grandparents, parents, children, siblings and other blood relatives.
The SENTIS™ Hereditary Cancer Panel analyses germline variants across over 100 cancer-predisposition genes, covering more than 20 hereditary cancer types,
